Skip to main content
. 2020 May 14;12(5):451. doi: 10.3390/pharmaceutics12050451

Table 3.

Analysis of variance of the final models for measured responses.

Parameters SS DF MS F p-Value Parameters SS DF MS F p-Value
Model EE% Model PDI
Cubic 22266.26 9 2474.03 50.3 <0.0001 Cubic 2.36 9 0.26 5.04 0.0002
A 351.4 1 351.4 7.2 0.0111 A 0.06 1 0.06 1.21 0.2793
B 1981.7 1 1981.7 40.3 <0.0001 B 0.67 1 0.67 12.79 0.0010
AB 3294.4 1 3294.4 67.0 <0.0001 AB 0.22 1 0.22 4.30 0.0451
A2 12.2 1 12.2 0.25 0.6220 A2 0.02 1 0.02 0.44 0.5092
B2 2570.3 1 2570.3 52.3 <0.0001 B2 0.68 1 0.68 13.01 0.0009
A2B 217.1 1 217.1 4.4 0.0425 A2B 0.28 1 0.28 5.34 0.0266
AB2 493.6 1 493.6 10.0 0.0031 AB2 0.10 1 0.10 1.98 0.1673
A3 40.9 1 40.9 0.83 0.3678 A3 0.09 1 0.09 1.73 0.1971
B3 781.9 1 781.9 15.9 0.0003 B3 0.62 1 0.62 11.83 0.0015
Parameters SS DF MS F p-Value Parameters SS DF MS F p-Value
Model Particle Size Model Zeta Potential
Cubic 3.6 × 10−3 9 4.0 × 10−4 30.1 <0.0001 Cubic 558.7 9 62.1 121.7 <0.0001
A 1.7 × 10−4 1 1.7 × 10−4 12.7 0.0010 A 9.1 1 9.1 17.8 0.0002
B 8.7 × 10−5 1 8.7 × 10−5 6.5 0.0152 B 0.67 1 0.67 1.3 0.2578
AB 1 × 10−4 1 1 × 10−4 7.35 0.0101 AB 5.4 1 5.4 10.5 0.0025
A2 2.9 × 10−7 1 2.9 × 10−7 0.02 0.8822 A2 5.3 1 5.3 10.5 0.0026
B2 6.6 × 10−4 1 6.6 × 10−4 49.1 <0.0001 B2 118.9 1 118.9 233.2 <0.0001
A2B 1.6 × 10−4 1 1.6 × 10−4 11.9 0.0014 A2B 35.9 1 35.9 70.4 <0.0001
AB2 1.2 × 10−4 1 1.2 × 10−4 8.8 0.0052 AB2 9.7 1 9.7 18.9 0.0001
A3 1.1 × 10−5 1 1.1 × 10−5 0.81 0.3726 A3 23.2 1 23.2 45.6 <0.0001
B3 2.4 × 10−4 1 2.4 × 10−4 17.6 0.0002 B3 25.2 1 25.2 49.3 <0.0001